3//SEC Filing
Bain Capital Life Sciences Investors, LLC 3
Accession 0000950170-25-004868
CIK 0001750284other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:31 PM ET
Size
23.8 KB
Accession
0000950170-25-004868
Insider Transaction Report
Form 3
Holdings
- 7,500,000(indirect: See footnotes)
Common Stock
- (indirect: See footnotes)
Pre-Funded Warrant (right to buy)
Exercise: $0.00From: 2024-12-04→ Common Stock (4,513,216 underlying)
Holdings
- (indirect: See footnotes)
Pre-Funded Warrant (right to buy)
Exercise: $0.00From: 2024-12-04→ Common Stock (4,513,216 underlying) - 7,500,000(indirect: See footnotes)
Common Stock
Holdings
- 7,500,000(indirect: See footnotes)
Common Stock
- (indirect: See footnotes)
Pre-Funded Warrant (right to buy)
Exercise: $0.00From: 2024-12-04→ Common Stock (4,513,216 underlying)
Holdings
- 7,500,000(indirect: See footnotes)
Common Stock
- (indirect: See footnotes)
Pre-Funded Warrant (right to buy)
Exercise: $0.00From: 2024-12-04→ Common Stock (4,513,216 underlying)
Holdings
- (indirect: See footnotes)
Pre-Funded Warrant (right to buy)
Exercise: $0.00From: 2024-12-04→ Common Stock (4,513,216 underlying) - 7,500,000(indirect: See footnotes)
Common Stock
Footnotes (4)
- [F1]Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV").
- [F2]Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- [F3]BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to such exercise.
- [F4]The pre-funded warrant does not expire.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001703031
Filing Metadata
- Form type
- 3
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 4:31 PM ET
- Size
- 23.8 KB